

**DONCASTER and BASSETLAW AREA PRESCRIBING COMMITTEE
MINUTES from 23rd February 2017**

Present:

<u>NHS Doncaster CCG</u>		<u>RDaSH FT</u>		<u>Doncaster LPC</u>	
Dr David Crichton – (APC Chair)		Mr Stephen Davies – Chief Pharmacist RDaSH FT	✓	Mr Paul Chatterton – LPC Representative	
Mr Mark Randerson- Head of Medicines Management (NHSD-MMT)	✓	Mr Andrew Houston - Senior Mental Health Pharmacist		Mr M Ahmed - Deputy	
Mrs Gill Bradley – Deputy Head of Medicines Management (NHSD-MMT)	✓	Dr Eric Dale - Consultant Psychiatrist RDaSH FT		<u>DBTHFT</u>	
Dr Rachel Sykes – NHS Doncaster GP	✓	Ms Anne Burton – Non Medical Prescriber Representative (RDaSH DCIS)	✓	Mr Andrew Barker – Chief Pharmacist DBTHFT	
<u>NHS Bassetlaw CCG</u>		Ms Julie Hall - Non Medical Prescriber Representative (RDaSH DCIS)		Mr Lee Wilson – Consultant Pharmacist DBTHFT	✓
Mr Rob Wise – Head of Medicines Management (BCCG)		<u>Doncaster LMC</u>		Dr Mahmoud Al Khoffash – Medical Director representative DBTHFT	✓
		Dr Dean Eggitt- LMC Secretary			
		Mr David Gibbons- LMC Deputy		<u>FCMS (When necessary)</u>	
	✓	Dr Rumit Shah – LMC Chair	✓	Mrs Nicola Sanders Mrs Tracey Edwards Mrs Alison O'Conner	

Minutes Only :- Dr Mark Pickering Doncaster Offender Health, Chair prisons D&T Committee

**Dr Rupert Suckling & Mr Victor Joseph DMBC
Mrs Nicola Sanders & Mrs Tracey Edwards FCMS**

In Attendance: Angie Machin – Minute Secretary (NHS Doncaster-MMT)

Agenda Item	Discussion Points	Action By
02/17/1	Apologies Apologies were received from Dr D Crichton, Mr P Chatterton, Dr D Eggitt & Mr R Wise	
02/17/2	Declarations of Interest, Gifts or Hospitality No declarations were received	
02/17/3	Minutes of last meeting The minutes of the last meeting held on the 26 th January were agreed as a true and accurate record and will be made available on the medicines management website.	

02/17/4.1	<p>Matters Arising</p> <ul style="list-style-type: none"> 01/17/5 Flunarizine The Committee was advised that there is no prescribing in Doncaster. 11/16/8.3 Denosumab SCP (Sheffield) DBFHFT enquired if patients using denosumab for osteoporosis being managed in Doncaster & Bassetlaw could also use the same process and paperwork as patients seen in Sheffield. The Committee agreed that this would be appropriate. 	
11/15/8.4	<p>Potential development of SCP/Pathway update for the management of ADHD in adults, young people and children.</p> <p>RDASHFT informed the Committee that the first draft of the shared care paperwork is now done. There are still some issues requiring work including:</p> <ul style="list-style-type: none"> The process to electronically record the centile chart to monitor height and weight as recommended by NICE. The pathway also needs to reflect the transition from child to adult care. DBFHFT Paediatrics will need to comment on the document <p>RDASH will share an electronic version with, along with the Commissioning Lead for Mental Health. This is to determine if the content aligns with the proposed pathway of care. A draft will then be shared by RDASH FT for the next APC meeting.</p>	RDaSHFT
10/16/8.2	<p>Parkinson's disease - SCP</p> <p>There is no progress with the update of the shared care paperwork. The Committee agreed that any drugs not Amber should be taken out of the paperwork and an Amber – G guidance document created (usual process) to support the on-going prescribing of these drugs in Primary Care. Amber drugs would remain in the Shared Care Protocol paperwork.</p> <p>The Committee agreed to a 2 month timeframe to complete this work.</p>	RDaSHFT
11/16/8.1	<p>Guidance for the Prescribing of Bicalutamide in the treatment of Prostate Cancer (Amber-G)</p> <p>The Committee received the document for approval, there had been no changes indicated. The Committee was advised that some of the references and links do require updating. There was also discussion around the 6 month monitoring and review process done in Secondary Care and the question as to if this will continue to be done was asked. DBFHFT confirmed that it would be done. The Committee agreed to check that the process was still in place in 2 years' time to ensure aberrant blood results are being actioned. The Committee approved the document on this basis and the updated version will be available on the medicines management website.</p>	NHSD-MMT(AM)

01/17/8.2	<p>Leeds Teaching Hospital Trust TLS NHSB-MMT attended the South Yorkshire & Bassetlaw Heads of Management meeting where the communication received from LTHT asking that CCG's should follow the traffic light classification for Leeds TLS when patients have been seen by their Secondary/Tertiary Care hospitals was discussed. The attending Y&H CCG's agreed that there had been a lack of engagement in the principles that the message delivered and there will be a need to consider prescribing responsibilities on a patient by patient basis.</p>	
01/17/8.4	<p>Midodrine The first draft of the Amber-G guidance was received by the Committee. The Committee requested that particular changes are fed back to DBFHFT including:</p> <ul style="list-style-type: none"> • The removal of the drug classification table • Clarification of the grade of clinician able to initiate prescribing • Monitoring schedules (differing from STH) <p>There were also a few other clinical questions requiring clarification therefore Dr Kersh Consultant in Medicine for Older People will be invited to the next APC meeting to aid further discussion. The Committee also agreed that a view from Dr Oates or Dr Craigmile (RDASHFT) should be sought as they also prescribe midodrine. RDASHFT agreed to request this.</p>	<p>NHSD- MMT (GB)</p> <p>RDASHFT</p>
01/17/17	<p>Methotrexate SC Injection A request made at last months meeting to consider the re-classification and shift of work load from Secondary to Primary care for methotrexate injections was again discussed. Dr Al Khoffash was unaware of this as he was not present at last month's meeting. Dr Al Khoffash explained the prescribing and supply process from both the Doncaster and Bassetlaw Rheumatology Departments. The initial request was made by Mr J Bane Deputy Chief Pharmacist from DBFHFT. Dr Al Khoffash agreed to speak with Mr Bane and Mr L Wilson outside of the meeting. The focus of the DBH FT internal discussion will be:</p> <ol style="list-style-type: none"> a. To establish what is a clinically safe and appropriate mechanism for prescribing, dispensing, delivery and disposal of SC Methotrexate b. To establish the financial impact of different models across the Doncaster and Bassetlaw community. 	Dr Al Khoffash
02/17/5	<p>Traffic Light – Drugs for Review All drugs for review were agreed as proposed, will be updated on the traffic light system and the details included in the Medicines Management T@blet Newsletter.</p> <p>Pomalidomide (Celgene) used in Multiple myeloma has now been categorised as Red 1,2,3 5-aminolaevulinic acid is now categorised for both Actinic keratosis on face and scalp & Basal cell carcinoma, it remains as Red 1,2</p>	NHSD- MMT(AM)
02/17/6	<p>APC Officers actions All officers actions were agreed as proposed, will be updated on the traffic light system.</p>	NHSD- MMT(AM)

02/17/7	<p>Traffic Light – Additions for Consideration All additions for consideration were agreed as proposed, will be updated on the traffic light system and the details included in the Medicines Management T@blet Newsletter.</p> <p>Saxagliptin/ Dapagliflozin (Qtern) used in Type 2 Diabetes has been categorised as Green – G, non-formulary Dalbavancin (Xydalba) used in acute bacterial skin & skin structure infections has been categorised as Red 1,2</p>	NHSD- MMT(AM)
02/17/8	New Business	
02/17/8.1	<p>SCP for the Management of Idiopathic Pulmonary Fibrosis with N-Acetylcysteine (Unlicensed Product) The protocol & proforma is now due for routine review. The paperwork will be passed to Dr Helen Meynell Consultant Pharmacist DBTHFT to update where/if necessary.</p>	NHSD- MMT(AM) /DBH FT
02/17/8.2	<p>Regional Medicines Optimisation Committee Operating Model Regional Medicines Optimisation Committees (RMOCs) will operate as a single medicines optimisation system for England, generating one output on any given topic. The work will be shared between 4 regional centres. The Committee received this document for information. NHSD-MMT attended a roadshow with additional workshops to demonstrate the operating of the committee. The original idea of providing new medicines evaluation is not going ahead therefore the focus is likely to be medicines optimisation. The RMOC will start to meet in April and the Committee will be informed of any further development in the future.</p>	
02/17/9	<p>DBTHFT D&TC Update No minutes available</p>	
02/17/10	<p>Formulary Liaison Group Update No minutes available</p>	
02/17/11	<p>Doncaster Prisons Drug & Therapeutic Committee No minutes available</p>	
02/17/12	<p>RDASH FT & Medicines Management Committee Update The minutes of the meeting held in November & December 2016 were received by the Committee</p>	
02/17/13	<p>Barnsley Area Prescribing Committee Update No minutes available</p>	
02/17/14	<p>Rotherham Area Prescribing Committee Update No minutes available</p>	
02/17/15	<p>Sheffield Area Prescribing Committee Update The minutes of the meeting held in November 2016 were received by the Committee</p>	
02/17/16	<p>Nottinghamshire Area Prescribing Committee Update The minutes of the meeting held in November 2016 were received by the Committee</p>	
02/17/17	<p>Any Other Business Flunarizine DBFHFT advised the Committee that Dr Ben Dorward, Neuro Sciences Pharmacist at STH has written a business case to support the use of flunarizine in a small number of patients. The paper has</p>	

	<p>been presented at the Medicines Safety Committee in Sheffield. NHSD-MMT will monitor the SCCG APC minutes to check for further developments. It has been confirmed that there is one patient from Doncaster receiving flunarizine from Sheffield and this should continue as long as there is clinical need.</p>	
02/17/18	<p>Date, time & venue of next meeting 12 noon prompt Thursday 30th March 2017 in Meeting Room 3 Sovereign House</p>	
	<p>12 noon prompt Thursday 27th April 2017 in Meeting Room 3 Sovereign House</p> <p>12 noon prompt Thursday 25th May 2017 in Meeting Room 3 Sovereign House</p> <p>12 noon prompt Thursday 29th June 2017 in Meeting Room 3 Sovereign House</p> <p>12 noon prompt Thursday 27th July 2017 in Meeting Room 3 Sovereign House</p> <p>12 noon prompt Thursday 31st August 2017 in Meeting Room 3 Sovereign House</p> <p>12 noon prompt Thursday 28th September 2017 in Meeting Room 3 Sovereign House</p>	